The role of CAR T-cell therapy in relapsed/refractory adult B-ALL
CAR T-cell therapy is a recent therapeutic advancement that has transformed the
management of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). To …
management of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). To …
Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: development, current status, and future directions
HM Kantarjian, N Boissel, C Papayannidis… - Cancer, 2024 - Wiley Online Library
Inotuzumab ozogamicin (InO) is an antibody‐drug conjugate approved for the treatment of
relapsed/refractory B‐cell acute lymphoblastic leukemia (ALL). Several clinical trials are …
relapsed/refractory B‐cell acute lymphoblastic leukemia (ALL). Several clinical trials are …
Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations
JD Rubinstein, MM O'Brien - Frontiers in Immunology, 2023 - frontiersin.org
Inotuzumab ozogamicin (InO) is an antibody drug conjugate composed of a humanized
monoclonal antibody targeting the cell surface receptor CD22 coupled to a cytotoxic …
monoclonal antibody targeting the cell surface receptor CD22 coupled to a cytotoxic …
Sequencing antigen‐targeting antibodies and cellular therapies in adults with relapsed/refractory B‐cell acute lymphoblastic leukemia
I Aldoss, BD Shah, JH Park, L Muffly… - American journal of …, 2023 - Wiley Online Library
The recent approvals of four CD19‐or CD22‐targeted therapies for B‐cell acute
lymphoblastic leukemia (B‐ALL) have transformed the treatment of relapsed/refractory (r/r) …
lymphoblastic leukemia (B‐ALL) have transformed the treatment of relapsed/refractory (r/r) …
Treatment of relapsed acute lymphocytic leukemia in adult patients
JC Molina, HE Carraway - Current Treatment Options in Oncology, 2024 - Springer
Opinion Statement For adult patients diagnosed with relapsed B cell-ALL (B-ALL), there
have been significant improvements in available treatment options following the FDA …
have been significant improvements in available treatment options following the FDA …
Management of ALL in adults: 2024 ELN recommendations from a European expert panel
N Gökbuget, N Boissel, S Chiaretti, H Dombret… - Blood, 2024 - ashpublications.org
Abstract Experts from the European Leukemia Net (ELN) working group for adult acute
lymphoblastic leukemia have identified an unmet need for guidance regarding management …
lymphoblastic leukemia have identified an unmet need for guidance regarding management …
Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
A Ferrari, D Cangini… - Frontiers in Cell and …, 2023 - frontiersin.org
High-risk relapsed/refractory adult Philadelphia-negative (Ph−) B-cell acute lymphoblastic
leukemia (B-ALL) is a great challenge due to limited possibilities to achieve and maintain a …
leukemia (B-ALL) is a great challenge due to limited possibilities to achieve and maintain a …
Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome–negative acute …
D Fischer, R Toenges, K Kiil, S Michalik… - Annals of …, 2024 - Springer
We present the case of a 58-year-old female patient who presented with an extramedullary
B-ALL relapse after prior allogenic HSCT and blinatumomab therapy. The patient died from …
B-ALL relapse after prior allogenic HSCT and blinatumomab therapy. The patient died from …
Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review
DI Marks, RD Cassaday, JM Ribera… - Expert Review of …, 2025 - Taylor & Francis
ABSTRACT Introduction Inotuzumab ozogamicin (InO) is indicated for the treatment of adults
with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). This systematic …
with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). This systematic …
[HTML][HTML] Tetraarsenic tetrasulfide triggers ROS-induced apoptosis and ferroptosis in B-cell acute lymphoblastic leukaemia by targeting HK2
W Bai, D Liu, Q Cheng, X Yang, L Zhu, L Qin… - Translational …, 2024 - Elsevier
Purpose Acute lymphoblastic leukemia (ALL) is the most common type of cancer diagnosed
in children. Despite cure rates of higher than 85%, refractory or relapsed ALL still exhibits a …
in children. Despite cure rates of higher than 85%, refractory or relapsed ALL still exhibits a …